Providers should monitor weight trajectory , GI tolerability (nausea, vomiting, constipation) , signs of pancreatitis (persistent severe abdominal pain vomiting), gallbladder disease (RUQ pain, fever, jaundice), hydration/renal function when clinically indicated (risk of AKI with severe GI effects), blood pressure , and glucose metrics (especially if combined with insulin or sulfonylureas due to hypoglycemia risk)
Citation on PubMed Rudwaleit M, van der Heijde D, Landewe R, Listing J, Akkoc N, Brandt J, Braun J, Chou CT, Collantes-Estevez E, Dougados M, Huang F, Gu J, Khan MA, Kirazli Y, Maksymowych WP, Mielants H, Sorensen IJ, Ozgocmen S, Roussou E, Valle-Onate R, Weber U, Wei J, Sieper J
Ginger chews you can carry in your pocket
These peptides are not suitable for anyone subject to athletic drug testing
7th edition